SAT-035 Small Molecule Allosteric Agonist of Relaxin Receptor Ml290 Demonstrates Antifibrotic Properties in Liver Fibrosis

Fibrosis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological therapeutic options. The beneficial effects of relaxin peptide treatment have been demonstrated previously in clinically relevant animal models of liver disease. However...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Endocr Soc
Autori principali: Kaftanovskaya, Elena, Ng, Hooi Hooi, Rivas, Bryan, Myhr, Courtney, Shupe, Thomas, Hu, Xin, Ferrer, Marc, Southall, Noel, Wilson, Kenneth, Marugan, Juan, Bishop, Colin, Agoulnik, Irina, Agoulnik, Alexander
Natura: Artigo
Lingua:Inglês
Pubblicazione: Endocrine Society 2019
Soggetti:
Non-Steroid Hormone Signaling
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552156/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-035
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi